TNF and Dupuytren Contracture: We anticipate the above recommendation to contribute to the planned economic analysis alongside the Repurposing Anti-TNF for Treating Dupuytren’s Disease (RIDD) trial (ISRCTN27786905 DOI 10.1186/ISRCTN27786905), which began recruiting patients in 2016.